Prostate Cancer - Results from #920

AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. May 21, 2024

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. May 21, 2024

SpaceOAR Complication Affecting the Treatment of Prostate Cancer. May 21, 2024

Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases. May 21, 2024

Prostate Risk and Monitoring During Testosterone Replacement Therapy. May 20, 2024

A Model-Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk. May 20, 2024

Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. May 20, 2024

Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer. May 20, 2024

Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. May 20, 2024

Variation in content discussed by specialty in consultations for clinically localized prostate cancer. May 20, 2024

Development and Validation of a Survey to Assess Sexual Health in Female Partners of Patients with Prostate Cancer. May 20, 2024

Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer. May 17, 2024

Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol. May 17, 2024

PSMA-Targeted Radiopharmaceuticals for Prostate Cancer Diagnosis and Therapy. May 17, 2024

Functional Outcomes and Quality of Life in High-risk Prostate Cancer Patients Treated by Robot-assisted Radical Prostatectomy with or Without Adjuvant Treatments. May 17, 2024

Accuracy, readability, and understandability of large language models for prostate cancer information to the public. May 16, 2024

Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review. May 16, 2024

Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents. May 16, 2024

Deciphering the Transcription Factor Landscape in Neuroendocrine Prostate Cancer Progression: A Novel Approach to Understand NE Transdifferentiation. May 16, 2024

The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b. May 16, 2024

Page 47 of 1438